Loading provider…
Loading provider…
Hematology & Oncology Physician in La Mesa, CA
NPI: 1134280605Primary Practice Location
GROSSMONT HOSPITAL
5555 Grossmont Center Dr, La Mesa, CA
Primary Employer
Cancer Center Oncology Medical Group, Inc-East County
grossmontcancercenter.com
HQ Phone
Get M.D. David's Phone Numberphone_androidMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1988 - 2027

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
University of California (San Diego) Medical Center
Fellowship • Hematology and Medical Oncology
1987 - 1989
Zucker School of Medicine at Hofstra/Northwell
Residency • Internal Medicine
1984 - 1987
Georgetown University School Of Medicine
som.georgetown.edu
Medical School
Until 1984
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 129 | 241 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 67 | 122 |
| 3 | 96372Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 28 | 180 |
| 4 | 96365Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 16 | 107 |
| 5 | 96413Infusion of chemotherapy into a vein up to 1 hour | 14 | 84 |
Efficacy and Safety of Paclitaxel Poliglumex as First-Line Chemotherapy in Patients at High Risk with Advanced-Stage Non–Small-Cell Lung Cancer: Results of a Phase II Study
Authors: Donald A. Richards, Paul Richards, David Bodkin, Marcus A. Neubauer, Fred Oldham
Publication Date: 2005-11
Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
Authors: Ronald Natale
Publication Date: 2009-05
Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy
Authors: Karen Kelly, Christopher G. Azzoli, Petr Zatloukal, Istvan Albert, Peter Y.Z. Jiang
Lead Sponsor: Bristol-Myers Squibb
Intervention / Treatment: DRUG: Placebo, DRUG: Carboplatin, DRUG: Ipilimumab, DRUG: Paclitaxel
Lead Sponsor: Astex Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Crizotinib, DRUG: AT13387